The Clinical trial of THROZEN Cough drops completed successfully. In Single-blind, Randomized, Clinical Study of THROZEN (Cough Drop Formulation), total numbers of patients screened were 230 and numbers of subjects enrolled for the study were 108. The Subjects were given the cough drop after they were enrolled in the study and were followed up for a period of fourteen days. There were two follow-up visits on day 07 and day 14.  The Cough and Sore throat severity, Dry mouth, Itching of throat, Voice quality, Redness of throat and Hoarseness were recorded during follow-up visits. 08 subjects discontinued after 07 days of study willingly. All the subjects studied showed a significant decrease in the frequency and severity of the cough and sore throat. No any adverse effects observed. If there are less intense symptoms, subjects have shown cure within 07 days course also. Assessment was based on improvement in symptoms, acceptability and overall efficiency and safety as reported by the physician and the subjects. Subjects showed positive response during the treatment period and the effects of cough drops are found satisfactory. The test drug THROZEN proved to be an effective and safe cough drop and highly acceptable for subjects with cough and sore throat. Thus, Throzen is clinically proven for its efficacy and safety.